StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
1470.TW$22.70+0.67%
Fair $22.70+0.0%

1470.TW

evertex fabrinology limited

Consumer Cyclical / Textile ManufacturingTaiwan

$22.70

+0.15 (+0.67%)

Fairly Valued+0.0%Fair Value $22.70Fund rank 37/100 · Data gapFallback financials|
SA 37/D
F-Score: 5/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $85.0M · quality 78.7/100

Data gap 37/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 76/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

37/100

D

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 1470.TWLocal privado en este navegador · evertex fabrinology limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.9B

P/E

29.1x

↑

EV/EBITDA

13.5x

↑

ROE

6.6%

↑

Gross Margin

24.2%

↓

Debt/Equity

0.04

↓
52-Week Range$23
$20$26

TradingView lightweight chart

1470.TW price, volumen y niveles de valoración

Último $22.65Periodo +35.7%
Fair value: $22.70

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-1.7%

FCF CAGR

-27.4%

FCF margin

7.7%

FCF / Net income

0.92x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $803.7M · net income $67.3M · FCF $62.1M

2022-FY → 2025-FY

Gross margin

24.2%+3.6% pts

Operating margin

10.4%+2.3% pts

Net margin

8.4%+4.5% pts

FCF margin

7.7%-11.5% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$803.7M$803.7M$788.0M$655.2M$845.2M
Net Income$67.3M$67.3M$97.3M$49.3M$32.8M
EBITDA$130.2M$130.2M$172.2M$108.4M$103.2M
EPS——1.130.570.38
Gross Margin24.2%24.2%25.3%19.8%20.6%
Operating Margin10.4%10.4%11.2%5.2%8.1%
Net Margin8.4%8.4%12.3%7.5%3.9%
Balance Sheet
Debt/Equity0.040.040.050.060.05
Current Ratio3.423.42———
Cash Flow
Free Cash Flow$62.1M$62.1M$85.0M$110.6M$162.2M
Returns
ROE6.6%6.6%9.4%5.0%3.4%
Valuation
P/E29.1029.1019.1632.8147.89
EV/EBITDA13.4913.499.4313.4513.78
P/B1.921.921.801.631.61
Growth & Yield
Revenue Growth2.0%2.0%20.3%-22.5%—
EPS Growth——98.2%50.0%—
Dividend Yield2.9%2.9%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -10.0%

Total return

-10.0%

Start / end P/E

n/dx → n/dx

EPS bridge

1.13 → n/d

Residual

-12.9%

EPS growthn/d
Multiple reratingn/d
Dividend+2.9%
Residual / FX / buybacks / cross-term-12.9%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.